|
1
|
Wu C, Li M, Meng H, Liu Y, Niu W, Zhou Y,
Zhao R, Duan Y, Zeng Z, Li X, et al: Analysis of status and
countermeasures of cancer incidence and mortality in china. Sci
China Life Sci. 62:640–647. 2019. View Article : Google Scholar
|
|
2
|
Zeng H, Chen W, Zheng R, Zhang S, Ji JS,
Zou X, Xia C, Sun K, Yang Z, Li H, et al: Changing cancer survival
in China during 2003-15: A pooled analysis of 17 population-based
cancer registries. Lancet Glob Health. 6:e555–e567. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vogt A, Schmid S, Heinimann K, Frick H,
Herrmann C, Cerny T and Omlin A: Multiple primary tumours:
Challenges and approaches, a review. ESMO Open. 2:e0001722017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Donin N, Filson C, Drakaki A, Tan HJ,
Castillo A, Kwan L, Litwin M and Chamie K: Risk of second primary
malignancies among cancer survivors in the United States, 1992
through 2008. Cancer. 122:3075–3086. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rasmussen LA, Jensen H, Virgilsen LF,
Falborg AZ, Møller H and Vedsted P: Healthcare utilisation in
general practice and hospitals in the year preceding a diagnosis of
cancer recurrence or second primary cancer: A population-based
register study. BMC Health Serv Res. 19:9412019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Barclay ME, Lyratzopoulos G, Walter FM,
Jefferies S, Peake MD and Rintoul RC: Incidence of second and
higher order smoking-related primary cancers following lung cancer:
A population-based cohort study. Thorax. 74:466–472. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jo JH, Cho IR, Jung JH, Lee HS, Chung MJ,
Bang S, Park SW, Chung JB, Song SY and Park JY: Clinical
characteristics of second primary pancreatic cancer. PLoS One.
12:e01797842017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Molina-Montes E, Pollán M, Payer T, Molina
E, Dávila-Arias C and Sánchez MJ: Risk of second primary cancer
among women with breast cancer: A population-based study in Granada
(Spain). Gynecol Oncol. 130:340–345. 2013. View Article : Google Scholar
|
|
9
|
Zheng X, Li X, Wang M, Shen J, Sisti G, He
Z, Huang J, Li YM and Wu A: Second primary malignancies among
cancer patients. Ann Transl Med. 8:6382020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Keegan THM, Bleyer A, Rosenberg AS, Li Q
and Goldfarb M: Second Primary malignant neoplasms and survival in
adolescent and young adult cancer survivors. JAMA Oncol.
3:1554–1557. 2017. View Article : Google Scholar
|
|
11
|
Simard JL, Kircher SM, Didwania A and Goel
MS: Screening for recurrence and secondary cancers. Med Clin North
Am. 101:1167–1180. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu Y, Cui P, Yang Z, Zhang P, Guo R and
Shao G: Right lower lobectomy eight years after left pneumonectomy
for a second primary lung cancer. J Cardiothorac Surg. 8:462013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu Y, Dong C and Chen L: The
clinicopathological features of second primary cancer in patients
with prior breast cancer. Medicine (Baltimore). 96:e66752017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li F, Zhong WZ, Niu FY, Zhao N, Yang JJ,
Yan HH and Wu YL: Multiple primary malignancies involving lung
cancer. BMC Cancer. 15:6962015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bian X, Wang K, Wang Q, Yang L, Xia J, Wu
W and Li L: The impact of a prior malignancy on outcomes in gastric
cancer patients. Cancer Med. 10:1457–1470. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
NCCN, . https://www.nccn.org/guidelines/category_1
|
|
17
|
Toma-Dasu I, Wojcik A and Kjellsson
Lindblom E: Risk of second cancer following radiotherapy. Phys Med.
42:211–212. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liang F, Zhang S, Xue H and Chen Q: Risk
of second primary cancers in cancer patients treated with
cisplatin: A systematic review and meta-analysis of randomized
studies. BMC Cancer. 17:8712017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Q, Shen Y, Ye B, Hu H, Fan C, Wang T,
Zheng Y, Lv J, Ma Y and Xiang M: Gene expression differences
between thyroid carcinoma, thyroid adenoma and normal thyroid
tissue. Oncol Rep. 40:3359–3369. 2018.PubMed/NCBI
|
|
20
|
Zhang H, Christensen CL, Dries R, Oser MG,
Deng J, Diskin B, Li F, Pan Y, Zhang X, Yin Y, et al: CDK7
Inhibition potentiates genome instability triggering anti-tumor
immunity in small cell lung cancer. Cancer Cell. 37:37–54.e9. 2020.
View Article : Google Scholar
|
|
21
|
Ireland AS, Micinski AM, Kastner DW, Guo
B, Wait SJ, Spainhower KB, Conley CC, Chen OS, Guthrie MR, Soltero
D, et al: MYC drives temporal evolution of small cell lung cancer
subtypes by reprogramming neuroendocrine fate. Cancer Cell.
38:60–78. e122020. View Article : Google Scholar
|
|
22
|
Na F, Pan X, Chen J, Chen X, Wang M, Chi
P, You L, Zhang L, Zhong A, Zhao L, et al: KMT2C deficiency
promotes small cell lung cancer metastasis through DNMT3A-mediated
epigenetic reprogramming. Nat Cancer. 3:753–767. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dong P, Deng L, Xin X, Luo D, Liu Z, Sun H
and Meng F: Risks of second primary malignancies among Chinese
cancer survivors at a single center during 2002–2016. Transl Cancer
Res. 7:257–267. 2018. View Article : Google Scholar
|
|
24
|
Feng RM, Zong YN, Cao SM and Xu RH:
Current cancer situation in China: Good or bad news from the 2018
Global Cancer Statistics? Cancer Commun (Lond). 39:222019.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wood ME, Vogel V, Ng A, Foxhall L, Goodwin
P and Travis LB: Second malignant neoplasms: Assessment and
strategies for risk reduction. J Clin Oncol. 30:3734–3745. 2012.
View Article : Google Scholar
|
|
26
|
Li Z, Wang K, Shi Y, Zhang X and Wen J:
Incidence of second primary malignancy after breast cancer and
related risk factors-Is breast-conserving surgery safe? A nested
case-control study. Int J Cancer. 146:352–362. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu Y, Zhang P, Zhang Y, Zheng L, Xu W,
Hou D and Kang Z: Clinical characteristics and overall survival
nomogram of second primary malignancies after prostate cancer, a
SEER population-based study. Sci Rep. 11:12932021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zang Y, Qi F, Cheng Y, Xia T, Xiao R, Li X
and Yang N: Survival outcomes in prostate cancer patients with a
prior cancer. Transl Androl Urol. 10:741–753. 2021. View Article : Google Scholar
|
|
29
|
Bright CJ, Reulen RC, Winter DL, Stark DP,
McCabe MG, Edgar AB, Frobisher C and Hawkins MM: Risk of subsequent
primary neoplasms in survivors of adolescent and young adult cancer
(Teenage and Young Adult Cancer Survivor Study): A
population-based, cohort study. Lancet Oncol. 20:531–545. 2019.
View Article : Google Scholar
|
|
30
|
Mahmood S, Vu K, Tai P, Joseph K, Koul R,
Dubey A and Yu E: Radiation-induced second malignancies. Anticancer
Res. 35:2431–2434. 2015.PubMed/NCBI
|
|
31
|
Berrington de Gonzalez A, Curtis RE, Kry
SF, Gilbert E, Lamart S, Berg CD, Stovall M and Ron E: Proportion
of second cancers attributable to radiotherapy treatment in adults:
A cohort study in the US SEER Cancer Registries. Lancet Oncol.
12:353–360. 2011. View Article : Google Scholar
|
|
32
|
Turcotte LM, Liu Q, Yasui Y, Henderson TO,
Gibson TM, Leisenring W, Arnold MA, Howell RM, Green DM, Armstrong
GT, et al: Chemotherapy and risk of subsequent malignant neoplasms
in the Childhood Cancer Survivor Study Cohort. J Clin Oncol.
37:3310–3319. 2019. View Article : Google Scholar
|
|
33
|
Morton LM, Swerdlow AJ, Schaapveld M,
Ramadan S, Hodgson DC, Radford J and van Leeuwen FE: Current
knowledge and future research directions in treatment-related
second primary malignancies. EJC Suppl. 12:5–17. 2014. View Article : Google Scholar
|
|
34
|
Adjei Boakye E, Buchanan P, Hinyard L,
Osazuwa-Peters N, Simpson MC, Schootman M and Piccirillo JF: Trends
in the risk and burden of second primary malignancy among survivors
of smoking-related cancers in the United States. Int J Cancer.
145:143–153. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Druesne-Pecollo N, Keita Y, Touvier M,
Chan DS, Norat T, Hercberg S and Latino-Martel P: Alcohol drinking
and second primary cancer risk in patients with upper aerodigestive
tract cancers: A systematic review and meta-analysis of
observational studies. Cancer Epidemiol Biomarkers Prev.
23:324–331. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Park SM, Li T, Wu S, Li WQ, Qureshi AA,
Stampfer M and Cho E: Risk of second primary cancer associated with
pre-diagnostic smoking, alcohol, and obesity in women with
keratinocyte carcinoma. Cancer Epidemiol. 47:106–113. 2017.
View Article : Google Scholar
|
|
37
|
Halamkova J, Kazda T, Pehalova L, Gonec R,
Kozakova S, Bohovicova L, Slaby O, Demlova R, Svoboda M and Kiss I:
The impact of diabetes mellitus on the second primary malignancies
in colorectal cancer patients. Front Oncol. 10:5733942021.
View Article : Google Scholar
|
|
38
|
Park SM, Lim MK, Jung KW, Shin SA, Yoo KY,
Yun YH and Huh BY: Prediagnosis smoking, obesity, insulin
resistance, and second primary cancer risk in male cancer
survivors: National Health Insurance Corporation Study. J Clin
Oncol. 25:4835–4843. 2007. View Article : Google Scholar
|
|
39
|
Khan SR, Chaker L, Ruiter R, Aerts JG,
Hofman A, Dehghan A, Franco OH and Stricker BH: Thyroid function
and cancer risk: The Rotterdam Study. J Clin Endocrinol Metab.
101:5030–5036. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hellevik AI, Asvold BO, Bjøro T,
Romundstad PR, Nilsen TI and Vatten LJ: Thyroid function and cancer
risk: A prospective population study. Cancer Epidemiol Biomarkers
Prev. 18:570–574. 2009. View Article : Google Scholar : PubMed/NCBI
|
